The surgical approach to total hip replacement (THR)--either from the front of the body or the side/back (anterior versus posterior)--has no impact on outcomes six months after surgery, according to research presented today at the 2016 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).

Researchers have identified a common ancestral gene that enabled the evolution of advanced life over a billion years ago. The gene, found in all complex organisms, including plants and animals, encodes for a large group of enzymes known as protein kinases that enabled cells to be larger and to rapidly transfer information from one part to another. 

Plants, animals, mushrooms and more all exist because they are made up of eukaryotic cells that are larger and far more complex than bacteria. Inside of these eukaryotic cells are hundreds of organelles that perform diverse functions to keep them living, just as different organs do for the human body.

Formaldehyde is back in the news because a company called Lumber Liquidators has been found to have exposure levels higher than previously believed. While three times effectively zero is still zero, fundraising groups like Natural Resources Defense Council have pounced on the opportunity to promote fear and doubt and talk about EPA regulations they have conspired with lobbyists to create.

Happy events can trigger a heart condition known as takotsubo syndrome, according to research published today (Thursday) in the European Heart Journal [1].

Takotsubo syndrome (TTS) is known as "broken heart syndrome" and is characterised by a sudden temporary weakening of the heart muscles that causes the left ventricle of the heart to balloon out at the bottom while the neck remains narrow, creating a shape resembling a Japanese octopus trap, from which it gets its name. Since this relatively rare condition was first described in 1990, evidence has suggested that it is typically triggered by episodes of severe emotional distress, such as grief, anger or fear, with patients developing chest pains and breathlessness. It can lead to heart attacks and death.

CHICAGO --- For women suffering from stage-4 breast cancer, there is a new treatment plan that, according to a recent Northwestern Medicine clinical trial, is highly effective and has minimal toxicity. The treatment includes a drug recently approved by the U.S. Food and Drug Administration.

The study combined palbociclib and fulvestrant to treat women with recurrent metastatic (advanced) breast cancer who are resistant to standard endocrine therapy. Patients who were treated with the two drugs experienced significantly longer periods of progression-free survival than those who received a placebo-plus-fulvestrant treatment.

A combination of two drugs delays progression of advanced, aggressive breast cancer by an average of nine months - working in all subsets of the most common type of breast cancer.

The combination - of a first-in-class targeted drug called palbociclib, and the hormone drug fulvestrant - slowed cancer growth in around two thirds of women with advanced forms of the most common type of breast cancer.

The combination allowed many women with metastatic hormone-receptor-positive, HER2-negative cancer to delay the start of chemotherapy, which is the traditional treatment option in these patients once hormone drugs have stopped working.